Business
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif., November 06, 2025--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today reported its third quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
About this update from Lineage Cell Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1740,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/2fa27a54ebbb22d5a65e0667a398b36c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/macUUQM2DjQIlKwEtLuXFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/2fa27a54ebbb22d5a65e0667a398b36c","width":960,"height":199},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/gSTEMYrD8RZLuqPJSBycMg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/2fa27a54ebbb22d5a65e0667a398b36c","width":1200,"height":248}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025","length":116,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for Sensorineural Hearing Loss","length":108,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Initiated Manufacturing Scale Project in Type 1 Diabetes Cell Therapy","length":69,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":293,"olType":false},{"type":"text","content":"CARLSBAD, Calif., November 06, 2025--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or "off the shelf", cell therapies for serious medical conditions, today reported its third quarter 2025 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.","length":452,"tagName":"p"},{"type":"text","content":""It has been a productive third quarter for the Lineage team," stated Brian M. Culley, Lineage CEO. "Last quarter, I outlined five areas of focus through the end of this year, and I am pleased to report that we delivered on several of these during the third quarter, as outlined below.","length":300,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"We entered into a research collaboration with William Demant Invest A/S, which is designed to fund all currently...